Patient utilization survey of mirabegron prescribed for overactive bladder

• Published in: Investigative and clinical urology 2019, 60(2), , pp.114-119
• Main Authors: Rahkola-Soisalo, Päivi, Balcerzak, Marcin, Ruotsalainen, Jarno, Mikkola, Tomi S
• Format: Article
• Language: English
• Subjects: Acetanilides - therapeutic use; Adrenergic beta-3 Receptor Agonists - therapeutic use; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Medication adherence; Medication Adherence - statistics & numerical data; Middle Aged; Original; Quality of Life; Self Report; Thiazoles - therapeutic use; urge; Urinary bladder; Urinary Bladder, Overactive - drug therapy; Urinary incontinence; Young Adult; 비뇨기과학
• ISSN: 2466-0493; 2466-054X
• DOI: 10.4111/icu.2019.60.2.114

Mirabegron, a β -adrenoreceptor agonist, is used to treat overactive bladder. The factors affecting persistence of mirabegron use or symptom improvement are not thoroughly known, but could be related to patient characteristics. Therefore, we evaluated persistence of medication use, symptom improvement, and quality of life among Finnish mirabegron users. In addition, we assessed possible predictors of change in these variables. Participants (52 men, 118 women) with an initial mirabegron prescription were recruited nationwide from 79 pharmacies. Volunteers were interviewed at baseline and after 6 months. Subject and clinical characteristics, symptom severity, and quality of life (EQ-5D-5L) were assessed using a visual analogue scale. Of 170 participants, 144 (84.7%) were reached after 6 months. The rate of persistent mirabegron use was 50.7%. Experiencing adverse effects (29.6%) was the most common reason for discontinuation of medication. A primary health care unit as a prescription site (odds ratio [OR], 2.3; 95% confidence interval [CI], 1.03-4.9) was associated with increased risk for discontinuation. Mirabegron relieved symptoms in 45.2% and enhanced quality of life in 41.7% of the participants. Age